Therapeutic strategy in p47-phox deficient chronic granulomatous disease presenting as inflammatory bowel disease

J Allergy Clin Immunol. 2010 Apr;125(4):943-946.e1. doi: 10.1016/j.jaci.2010.01.035.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Age of Onset
  • Anti-Bacterial Agents / therapeutic use
  • Antibodies, Monoclonal / therapeutic use
  • Child
  • Drug Therapy, Combination
  • Gene Deletion
  • Granulomatous Disease, Chronic / diagnosis
  • Granulomatous Disease, Chronic / drug therapy*
  • Granulomatous Disease, Chronic / genetics
  • Granulomatous Disease, Chronic / physiopathology*
  • Humans
  • Inflammatory Bowel Diseases / drug therapy*
  • Inflammatory Bowel Diseases / physiopathology*
  • Male
  • NADPH Oxidases / deficiency*
  • NADPH Oxidases / genetics
  • Steroids / therapeutic use
  • Treatment Outcome
  • Vidarabine / analogs & derivatives
  • Vidarabine / therapeutic use

Substances

  • Anti-Bacterial Agents
  • Antibodies, Monoclonal
  • Steroids
  • NADPH Oxidases
  • neutrophil cytosolic factor 1
  • Vidarabine
  • fludarabine